This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
by Zacks Equity Research
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
FATEPositive Net Change SPRONegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
by Zacks Equity Research
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
GSKPositive Net Change INCYPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology medical pharmaceuticals
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MISTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
by Zacks Equity Research
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
PFEPositive Net Change GILDNegative Net Change ACRSPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Nov 19, 2024
by Zacks Equity Research
Companies In The News Are: TWST, CVS, OKLO, HSIC.
HSICNegative Net Change CVSPositive Net Change TWSTNegative Net Change OKLONegative Net Change
alt-energy biotechnology medical retail
A.P. Moller-Maersk (AMKBY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMKBYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
by Zacks Equity Research
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
PFEPositive Net Change GILDNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
by Zacks Equity Research
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bull Of The Day: Tactile Systems Technology (TCMD)
by Brian Bolan
This stock consistently beats the number and treats underdiagnosed chronic diseases that could get more attention with the changes coming to the government
TCMDPositive Net Change
biotechnology biotechs medical medical-devices
Stock Market News for Nov 18, 2024
by Zacks Equity Research
Wall Street continues its decline on Friday following the Fed Chairman???s hawkish statement on rate cut.
PFEPositive Net Change AMGNPositive Net Change MRNAPositive Net Change
biotechnology pharmaceuticals
Trump Taps RFK for HHS: Time to Avoid Biotech?
by Andrew Rocco
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers. Stock Strategist Andrew Rocco explains.
PFEPositive Net Change NVOPositive Net Change MCDNegative Net Change MRNAPositive Net Change XBIPositive Net Change
biotechnology biotechs
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
NVSPositive Net Change PFEPositive Net Change KODPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
by Zacks Equity Research
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
NVAXPositive Net Change RNAPositive Net Change SNDXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
by Zacks Equity Research
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
BIIBPositive Net Change ABBVPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Upwork (UPWK) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
UPWKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Air Canada (ACDVF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ACDVFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
XNCRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ametek (AME) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AMENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Midland States Bancorp (MSBI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MSBINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
BIIBPositive Net Change TBPHPositive Net Change ALLOPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
ANIPNegative Net Change FATEPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BIIBPositive Net Change NBIXPositive Net Change XENEPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Nov 13, 2024
by Zacks Equity Research
Companies In The News Are: MOS, RGEN, SE, FOUR.
SEPositive Net Change MOSPositive Net Change RGENNegative Net Change FOURPositive Net Change
basic-materials biotechnology business-services internet
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings pharmaceuticals